LivaNova met the primary endpoints for its OSPREY trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation.

LivaNova (Nasdaq:LIVN) today announced that its OSPREY trial of nerve stimulation for treating sleep apnea met its primary ...

LivaNova (LIVN) “announced that it met the primary endpoints for its OSPREY randomized controlled trial, Treating Obstructive Sleep Apnea Using Targeted Hypoglossal Nerve Stimulation. Together with ...

As Veterans Day approaches, those who served our nation face a quiet healthcare crisis. The Department of Veterans Affairs ...